VANDERBILT UNIVERSITY

Funding Organization

Awards Grant

  • A Phase II Neo-Adjuvant Study of Cisplatin, Paclitaxel With or Without RAD001 in Patients with Triple-Negative Locally Advanced Breast Cancer
  • AIDS Education and Training Centers Program
  • Bruton's Tyrosine Kinase and Immune Tolerance in Type 1 Diabetes
  • Cohort Study of Cancer-Inhibitory Dietary Factors in Men
  • Early Career Translational Research Award in Biomedical Engineering
  • High VS. Standard Dose Flu Vaccine in Adult Stem Cell Transplant Recipients
  • IUAB 1677: Optimizing Post-Allogeneic Hematopoietic Cell Transplant Outcomes for Lymphoma using Ibrutinib
  • Impact of MMA on Health-Related and Functional Outcomes
  • Increased Cardiovascular Risk and Early Natural Menopause in a Biracial Cohort
  • Instructional Training for Vanderbilt University-CIDRZ AIDS International Training and Research Program
  • Lipids and Inflammation
  • Multi-Level Social and Behavioral Determinants of Health and Missed HIV Healthcare Provider Visits
  • Multidisciplinary Approaches To HDL Structure, Assembly And Function
  • Multidisciplinary Approaches to HDL Structure, Assembly and Function
  • Obesity, Salt-Sensitivity, and Natriuretic Peptides
  • Prospective Observation of Cardiac Safety with Proteasome Inhibition (PROTECT)
  • Regulation of RNA Editing in the CNS
  • Role of the MC3-R in Obesity and Metabolic Syndrome
  • Surgical Treatment of Obstructive Sleep Apnea by Maxillomandibular Advancement
  • Timing of Inguinal Hernia Repair in Premature Infants: A Randomized Trial
  • Trajectory of Anti-Mullerian Hormone Decline and CVD Risk in CARDIA Women
  • Transforming STEM Learning in Urban Schools Using the SSMV Model
  • UAB 1198: A Phase II Neo-Adjuvant Study of Cisplatin, Paclitaxel with or without RAD001 in Patients with Triple-Negative Locally Advanced Breast Cancer
  • UAB 1640-Phase II Trial of Vosaroxin in Combination with Infusional Cytarabine in Patients with Untreated AML
  • UAB17127:A phase Ib trial of fulvestrant, palbociclib (CDK4/6 inhibitor) and erdafitinib (JNJ- 42756493, pan-FGFR tyrosine kinase inhibitor) in ER+/HER2–/FGFR-amplified metastatic breast cancer (MBC)
  • Vaccine and Treatment Evaluation Units - Admin Task